|
| 38053317 | Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential. | Vet Comp Oncol | 2024 |
| 36609061 | Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. | | 2023 |
| 36335489 | Interrogating the Human Diplome: Computational Methods, Emerging Applications, and Challenges. | Methods Mol Biol | 2023 |
| 37603953 | Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma. | Neoplasia | 2023 |
| 36630480 | Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer. | Sci Transl Med | 2023 |
| 37248814 | Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC. | | 2023 |
| 35852795 | Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. | Clin Cancer Res | 2022 |
| 35355452 | A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. | Cancer Rep (Hoboken) | 2022 |
| 34610968 | Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. | Cancer Res | 2021 |
| 33826614 | Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. | PLoS One | 2021 |
| 32661119 | Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. | Journal for ImmunoTherapy of Cancer | 2020 |
| 32743548 | Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. | Neurooncol Adv | 2020 |
| 30949446 | Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples. | Front Oncol | 2019 |
| 31651965 | Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. | JAMA Netw Open | 2019 |
| 31881020 | Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. | PLoS One | 2019 |
| 30264293 | E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. | Invest New Drugs | 2019 |
| 30537101 | Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. | Molecular Oncology | 2019 |
| 30861105 | A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. | Int J Cancer | 2019 |
| 31209844 | Genomics-Enabled Precision Medicine for Cancer. | Cancer Treatment and Research | 2019 |
| 29074604 | Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. | Clin Cancer Res | 2018 |
| 30322893 | Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses. | Cold Spring Harbor molecular case studies | 2018 |
| 28314589 | FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. | Gynecologic Oncology | 2017 |
| 28586388 | A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. | PLoS One | 2017 |
| 28446508 | Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. | Clin Cancer Res | 2017 |
| 29052513 | A method to reduce ancestry related germline false positives in tumor only somatic variant calling. | BMC Med Genomics | 2017 |
| 26991655 | Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. | PLoS One | 2016 |
| 26996076 | Translating RNA sequencing into clinical diagnostics: opportunities and challenges. | Nat Rev Genet | 2016 |
| 25934816 | Toward precision medicine in glioblastoma: the promise and the challenges. | Neuro Oncol | 2015 |
| 25592568 | An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine. | Pac Symp Biocomput | 2015 |
| 25237832 | Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway. | Oncotarget | 2014 |
| 23059386 | XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. | Anti-Cancer Drugs | 2013 |
| 23908597 | The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. | Neoplasia | 2013 |
| 23039341 | Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. | Molecular Cancer | 2012 |
| 22383975 | FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. | PLoS ONE | 2012 |
| 23060048 | Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. | International Journal of Gynecological Cancer | 2012 |
| 23056468 | Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer. | PLoS ONE | 2012 |
| 20106510 | FGFR2 mutations are rare across histologic subtypes of ovarian cancer. | Gynecologic Oncology | 2010 |
| 19147536 | Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. | Mol Cancer Res | 2009 |
| 19243295 | FGFR2 as a molecular target in endometrial cancer. | Future Oncology | 2009 |
| 19564416 | Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. | Mol Cell Biol | 2009 |
| 18757403 | Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. | Cancer Research | 2008 |
| 18819936 | Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. | Molecular Cancer Research | 2008 |
| 18829493 | Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. | Clinical Cancer Research | 2008 |
| 17043687 | Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. | British Journal of Cancer | 2006 |
| 14613033 | Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. | Seminars in Oncology | 2003 |